GenomeKey
GenomeKey is a Bristol-based diagnostics company building an automated IVD device and cloud bioinformatics platform that use whole genome sequencing and machine learning to identify bacterial pathogens and AMR profiles from patient blood in hours, targeting hospitals and NHS Trusts.
- Company typePrivate
- Founded2019
- HeadquartersBristol, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What GenomeKey does
GenomeKey (operating as Genomic Labs Ltd.) is a Bristol, UK-based diagnostics company founded in 2019 that is developing a next-generation in vitro diagnostic (IVD) device for the rapid identification of bacterial pathogens and their antimicrobial resistance (AMR) profiles directly from patient blood. The company's flagship product, GenomeKeyDx, is a benchtop automated device designed to detect bacteria in two hours, identify species within three hours, and deliver a full AMR profile in five hours — a turnaround compression from the 2-3 day standard for blood culture-based diagnostics and an attempt to address the fact that one in three sepsis deaths occur before current test results return. GenomeKey's underlying technology combines a proprietary bacterial DNA extraction process (reportedly shifting the human-to-bacterial DNA ratio from 2 billion:1 to 1:1) with whole genome sequencing — sourced via a core partnership with Oxford Nanopore Technologies — and proprietary machine learning algorithms for genome interpretation and AMR prediction.
The company operates two product lines: the GenomeKeyDx IVD device, currently in prototype/development and targeting CE marking, aimed at hospital emergency departments, ICUs, and clinical microbiology laboratories; and the GenomeKey Platform, a cloud-based bioinformatics SaaS available globally with freemium, Premium (£500/user/month), and Ultimate (custom) tiers. Go-to-market centers on enterprise field sales into NHS Trusts in the UK for clinical evaluations (currently active across two NHS sites), with stated global ambitions but no disclosed commercial revenues. Underlying sequencing is enabled by Oxford Nanopore's real-time, long-read platform, and compute/ecosystem support is supplemented through the NVIDIA Inception program.
GenomeKey's revenue model is bifurcated between (a) a self-serve SaaS bioinformatics platform with disclosed tiered pricing and (b) future hardware sales of the GenomeKeyDx device, where the company has signaled comparable per-test economics to existing UK sepsis tests (£100–£120 per test). To date, the company has not disclosed commercial revenue; its funding is dominated by non-dilutive grants, including a US$11.4M CARB-X award in 2024 to build an automated prototype, an earlier CARB-X award of US$3M in 2021, and support from InnovateUK. The company employs approximately 30 people across science, engineering, machine learning, and operations, and appointed diagnostics-industry veteran Randy Pritchard (former Roche Diagnostics SVP and ex-CEO/Board Member of Pillar Biosciences) as Chair of the Board in December 2024.
GenomeKey firmographics
Firmographics- Name
- GenomeKey
- Legal name
- Genomic Labs Ltd.
- Website
- https://genomekey.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- GenomeKey is a Bristol-based diagnostics company building an automated IVD device and cloud bioinformatics platform that use whole genome sequencing and machine learning to identify bacterial pathogens and AMR profiles from patient blood in hours, targeting hospitals and NHS Trusts.
- Ownership category
- akta.pro rank
GenomeKey industry classification
Industry- Product category
- In Vitro Diagnostics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511), Analytical Laboratory Instrument Manufacturing (334516), Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services (518)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841), Services-Prepackaged Software (7372), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL)
- akta.pro secondary industries
- Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF), Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD), Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF)
Keywords
Where GenomeKey is headquartered
LocationHeadquarters
- HQ city
- Bristol
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
GenomeKey business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- GenomeKeyDx IVD Device Sales: Revenue from sale of the next-generation in vitro diagnostic device for bacterial identification and AMR profiling in hospitals and healthcare settings. Currently in development with prototype phase.
- GenomeKey Platform Software: Cloud-based bioinformatics platform with tiered pricing (Free, Premium £500/user/month, Ultimate custom pricing). Free tier for industrial and healthcare users with valid AST results; Premium and Ultimate tiers for scalable bioinformatics, automatic reports, and sequencing support.
- R&D and Clinical Partnership Funding: Non-dilutive funding from partnerships such as CARB-X (US$11.4M award) and InnovateUK for product development and clinical validation.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Freemium | Monthly | Free tier - Free forever for industrial and healthcare users |
| Subscription | Monthly | Premium tier - £500 per user per month |
| Subscription | Multi-year contract | Ultimate tier - Custom pricing |
| Unit Pricing | Pay-as-you-go | IVD Device Test Cost |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels6 records
GenomeKey product offering
Product offeringCore offering
GenomeKey develops the GenomeKeyDx, a next-generation in vitro diagnostic (IVD) device that performs whole genome sequencing and machine-learning-based interpretation directly from patient blood to detect bacteria, identify species, and deliver a full antimicrobial resistance (AMR) profile in hours rather than days. The company also operates the GenomeKey Platform, a cloud-based bioinformatics SaaS offering tiered automated bacterial identification and AMR analysis for labs and industrial users.
Product overview
GenomeKey offers two interconnected products: GenomeKeyDx, a benchtop IVD device, and the GenomeKey Platform, a software bioinformatics solution. The IVD device performs bacterial DNA extraction and whole genome sequencing directly from patient blood, while the platform provides automated analysis and reporting for labs uploading AST results. Both products leverage machine learning for species identification and AMR profiling to enable targeted antibiotic treatment within hours.
Differentiator
Problem solved
Functional benefit
Products and services
- GenomeKeyDx Next-generation in vitro diagnostic (IVD) device that detects bacteria, identifies species, and provides a full antimicrobial resistance (AMR) profile directly from patient blood in hours rather than days, using proprietary DNA extraction and machine-learning interpretation. Intended for hospital clinical microbiology labs, emergency departments and ICUs treating sepsis patients.
- GenomeKey Platform Cloud-based bioinformatics SaaS that performs automated bacterial identification and antimicrobial resistance analysis, with tiered pricing for industrial and healthcare users uploading valid AST results. Generates automatic reports and offers bespoke reporting and sequencing support on enterprise tiers.
Quantifiable outcome
- Bacterial detection time reduced from 2-3 days to 2 hours
- +4 more outcomes
Companies that use GenomeKey
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles3 records
GenomeKey technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature4 records
GenomeKey partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and supporting.
- NHS TrustscoreGenomeKey works closely with the NHS to ensure technology is designed with end-user needs in mind. Through NHS partners, the company is able to trial and evaluate their technology. Solutions are being evaluated across two different NHS sites.
- NVIDIAsupportingThe NVIDIA Inception program supports GenomeKey development through access to cutting-edge technology and NVIDIA experts, opportunities to connect with venture capitalists, and co-marketing support.
- SetSquared BristolsupportingSetSquared Bristol is a business incubator and support program that supports GenomeKey to grow and succeed. They provide a range of resources and services including business development support and networking with other entrepreneurs.
- West of England Academic Health Science Network (WE-AHSN)supportingPart of a network of organisations that aims to improve healthcare and support innovation in the healthcare sector by providing access to expertise and healthcare institutions.
- Oxford Nanopore TechnologiescoreCollaboration to develop a new diagnostic tool for bloodstream infections. Oxford Nanopore's sequencing technology can analyse native DNA or RNA and sequence any length of fragment. The rich, real-time data enables rapid detection, identification, and evaluation of antimicrobial susceptibility in hours rather than days. GenomeKey receives continued support and access to latest technologies from Oxford Nanopore.
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
GenomeKey competitors and assessment
Company assessmentDirect peers
- bioMérieux (BioFire Diagnostics): bioMérieux's BioFire Blood Culture Identification panels are the dominant molecular sepsis diagnostic in clinical use today. Both companies target rapid bacterial identification and resistance profiling from positive blood cultures, and bioMérieux is the entrenched incumbent GenomeKey must displace or partner with for hospital adoption.
- Q-linea: Q-linea develops the ASTar system for rapid antimicrobial susceptibility testing from positive blood cultures, addressing the same clinical need as GenomeKey's AMR profiling output. Both companies compete to shorten the time from blood draw to targeted antibiotic therapy in sepsis management.
- T2 Biosystems: T2 Biosystems developed T2Bacteria and T2Candida direct-from-blood molecular panels for sepsis diagnosis, the most direct comparable to GenomeKey's rapid bacterial ID from whole blood. GenomeKey's CCO Chris Brain previously led commercialization at T2, and both target the same unmet need of replacing days-long blood cultures in hospital sepsis workflows.
- Accelerate Diagnostics: Accelerate Diagnostics offers the Accelerate Pheno system for rapid identification and antimicrobial susceptibility testing direct from positive blood cultures, targeting the same hours-not-days sepsis workflow that GenomeKey is building toward. Comparable use case, customer base, and hospital procurement motion.
Emerging players
- Selux Diagnostics: Selux Diagnostics is developing rapid phenotypic antimicrobial susceptibility testing with single-cell resolution, targeting the same AMR profiling use case as GenomeKey. Comparable early-stage positioning in the rapid AST market with hospital microbiology labs as primary customers.
- Specific Diagnostics: Specific Diagnostics (acquired by bioMérieux) developed a rapid phenotypic AST technology based on volatile organic compound detection. Direct overlap with GenomeKey's AMR profiling goal, though using a fundamentally different detection method—useful for competitive benchmarking on speed and accuracy.
- Resistell: Resistell (Switzerland) is developing nanomotion-based rapid antibiotic susceptibility testing direct from clinical samples, addressing the same AMR profiling opportunity as GenomeKey. Comparable early-stage Swiss/UK European diagnostics competitor with similar AMR-focused value proposition.
Broad incumbents
- Cepheid (Danaher): Cepheid's GeneXpert system is a widely deployed molecular diagnostics platform in hospitals, including for bloodstream infections. While broader in scope than GenomeKey, it competes for the same hospital capital budget and clinical microbiology workflow share, and could be a potential commercialization or acquisition partner.
- Roche Diagnostics: Roche's discontinued SeptiFast (referenced in GenomeKey's CCO background) was a direct-from-blood sepsis molecular test, and Roche remains the largest IVD incumbent with global hospital reach. Represents both a benchmark for prior attempts at rapid sepsis diagnostics and a potential global commercialization/acquisition partner.
Others
- Oxford Nanopore Technologies: Oxford Nanopore is GenomeKey's core sequencing technology partner and supplies the nanopore platform underlying the GenomeKeyDx device. While not a direct competitor in sepsis IVDs, Oxford Nanopore's own clinical diagnostics ambitions and product roadmap materially shape GenomeKey's technology trajectory and IP positioning.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
GenomeKey social profiles
Digital presenceGenomeKey financial estimates
Financial estimateRevenue estimate
Valuation estimate
GenomeKey leadership team
Management profileNumber of profiles
Profiles9 records
GenomeKey funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
GenomeKey M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about GenomeKey
What does GenomeKey do?
GenomeKey develops the GenomeKeyDx, a next-generation in vitro diagnostic (IVD) device that performs whole genome sequencing and machine-learning-based interpretation directly from patient blood to detect bacteria, identify species, and deliver a full antimicrobial resistance (AMR) profile in hours rather than days. The company also operates the GenomeKey Platform, a cloud-based bioinformatics SaaS offering tiered automated bacterial identification and AMR analysis for labs and industrial users.
Is GenomeKey a public or private company?
GenomeKey is a private company. It is classified as venture growth investor backed and is currently operating.
When was GenomeKey founded?
GenomeKey was founded in 2019. It employs 11 to 50 people.
Where is GenomeKey based?
GenomeKey is headquartered in Bristol, United Kingdom, in the Europe region.
How does GenomeKey make money?
Three revenue lines are on record. GenomeKeyDx IVD Device Sales are the primary driver. The others are genomeKey Platform Software and R&D and Clinical Partnership Funding.
Who are GenomeKey's main competitors?
Direct peers on record are bioMérieux (BioFire Diagnostics), Q-linea, T2 Biosystems and Accelerate Diagnostics. Emerging players are Selux Diagnostics, Specific Diagnostics and Resistell. Broad incumbents are Cepheid (Danaher) and Roche Diagnostics. Oxford Nanopore Technologies is listed as an others.
Does GenomeKey have an API?
No public API is recorded for GenomeKey.
What industry is GenomeKey in?
GenomeKey's product category is In Vitro Diagnostics. Its primary akta.pro industry code is HLAAALAL, Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays), with a secondary code of HLAGADAF, Molecular & Genetic Testing (PCR/NGS/qPCR). Its NAICS code is 541714 and its SIC code is 2835.